Ravi Srinivasan, i2o Therapeutics CEO

J&J and Sanofi-part­nered oral de­liv­ery biotech rais­es $26M on lat­est of­fer­ing

Ac­cord­ing to an SEC fil­ing Tues­day, i2o Ther­a­peu­tics raised $26 mil­lion in a pri­vate stock of­fer­ing.

The Har­vard spin­out start­ed out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.